期刊
BIOMEDICINES
卷 10, 期 12, 页码 -出版社
MDPI
DOI: 10.3390/biomedicines10123008
关键词
acute myeloid leukemia; tumor agnostic; solid tumor; genomic profiling; hereditary breast and ovarian cancer; variant; molecular-targeted therapy; BRCA
资金
- National Cancer Research and Development expense grant
- National Cancer Center, Japan
- [2021-A-11]
Comprehensive genomic profiling examinations have led to the development of new molecular-targetable therapies across solid tumors, while elucidation of hereditary tumors has paved the way for new treatments and management strategies. In the context of AML, there is a lack of focus on tumor-agnostic or hereditary mutations and associated molecular-targeted therapies. Studies on tumor-agnostic mutations in AML are exploring the potential for targeted therapies.
Comprehensive genomic profiling examinations (CGPs) have recently been developed, and a variety of tumor-agnostic mutations have been detected, leading to the development of new molecular-targetable therapies across solid tumors. In addition, the elucidation of hereditary tumors, such as breast and ovarian cancer, has pioneered a new age marked by the development of new treatments and lifetime management strategies required for patients with potential or presented hereditary cancers. In acute myeloid leukemia (AML), however, few tumor-agnostic or hereditary mutations have been the focus of investigation, with associated molecular-targeted therapies remaining poorly developed. We focused on representative tumor-agnostic mutations such as the TP53, KIT, KRAS, BRCA1, ATM, JAK2, NTRK3, FGFR3 and EGFR genes, referring to a CGP study conducted in Japan, and we considered the possibility of developing molecular-targeted therapies for AML with tumor-agnostic mutations. We summarized the frequency, the prognosis, the structure and the function of these mutations as well as the current treatment strategies in solid tumors, revealed the genetical relationships between solid tumors and AML and developed tumor-agnostic molecular-targeted therapies and lifetime management strategies in AML.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据